國家衛生研究院 NHRI:Item 3990099045/12591
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 914799      Online Users : 1415
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12591


    Title: Management of early stage gastro-oesophageal cancers: Expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
    Authors: Roy, AC;Shapiro, J;Burge, M;Karapetis, CS;Pavlakis, N;Segelov, E;Chau, I;Lordick, F;Chen, LT;Barbour, A;Tebbutt, N;Price, T
    Contributors: National Institute of Cancer Research
    Abstract: Introduction: A multimodal approach in operable early stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes.Areas covered: A review of the published literature and conference abstracts was undertaken on the topic of optimal adjunctive chemotherapy or chemoradiotherapy in early stage OG cancers. This review article focuses on the current evidence pertaining to neo-adjuvant and perioperative strategies in curable OG cancers including the evolving landscape of immunotherapy and targeted drugs in this setting.Expert commentary: Adjunctive therapies in the form of pre-operative chemo-radiotherapy (CRT) or chemotherapy and perioperative chemotherapy over surgery alone improves outcomes in patients with operable OG cancer. Although there are variations in practice around the world, a multi-disciplinary approach to patient care is of paramount importance. Immunotherapy and on treatment functional imaging are two examples of emerging strategies to improve outcome for early stage patients. Better understanding of the molecular biology of this disease may help overcome the problem of tumour heterogeneity and enable more rationally designed and targeted therapeutic interventions in the future.
    Date: 2020-04
    Relation: Expert Review of Anticancer Therapy. 2020 Apr;20(4):305-324.
    Link to: http://dx.doi.org/10.1080/14737140.2020.1746185
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1473-7140&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000526683900001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85083549325
    Appears in Collections:[Li-Tzong Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB32202178.pdf822KbAdobe PDF261View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback